Contemporary epidemiology of renal cell cancer

Cancer Journal

Volumn 14, Issue 5, 2008, Pages 288-301

  Chow, Wong Ho ^a   Devesa, Susan S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cohort studies; Diet; Genetic polymorphism; Hypertension; Incidence trends; Obesity; Occupation; Renal cell cancer; Smoking; Somatic mutation

Indexed keywords

ALCOHOL; TRICHLOROETHYLENE; TUMOR MARKER;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY WEIGHT; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; DIET; ENVIRONMENTAL FACTOR; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HOST SUSCEPTIBILITY; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CELL; MAJOR CLINICAL STUDY; MALE; OBESITY; OCCUPATIONAL EXPOSURE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SMOKING; SOMATIC MUTATION; TUMOR VOLUME; UNITED STATES; VON HIPPEL LINDAU DISEASE;

EID: 55349114046     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181867628     Document Type: Article

References (206)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628-1631.
3. Verhoest G, Veillard D, Guillé F, et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol. 2007;51:1298-1305.
4. Zambrano NR, Lubensky IA, Merino MJ, et al. Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol. 1999;162:1246-1258.
5. Zbar B, Lerman M. Inherited carcinomas of the kidney. Adv Cancer Res. 1998;75:163-201.
6. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol. 2002;26:1542-1552.
7. Merino MJ, Torres-Cabala C, Pinto P, et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31:1578-1585.
8. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. JAMA. 1995;273:564-570.
9. Vaishampayan UN, Do H, Hussain M, et al. Racial disparity in incidence patterns and outcome of kidney cancer. Urology. 2003;62: 1012-1017.
10. Stafford HS, Saltzstein SL, Shimasaki S, et al. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol. 2008;179:1704-1708.
11. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2005 [Based on November 2007 SEER data submission]. Bethesda, MD: National Cancer Institute, 2008. Available at: http://seer.cancer.gov/csr/ 1975_2005/, posted to the SEER web site.
12. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Limited-Use, Nov 2007 Sub (1973-2005)
13. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 13 Regs Limited-Use, Nov 2007 Sub (1992-2005)
14. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (1973-2005 varying)-Linked To County Attributes - Total U.S., 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Available at: www.seer.cancer.gov. Released April 2008, based on the November 2007 submission.
15. Surveillance Research Program, National Cancer Institute SEER*Stat Software. Available at: www.seer.cancer.gov/seerstat, version 6.4.4.
16. Mathew A, Devesa SS, Fraumeni JF Jr, et al. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev. 2002;11:171-178.
17. Katz DL, Zheng T, Holford TR, et al. Time trends in the incidence of renal carcinoma: analysis of Connecticut Tumor Registry data, 1935-1989. Int J Cancer. 1994;58:57-63.
18. Liu S, Semenciw R, Morrison H, et al. Kidney cancer in Canada: the rapidly increasing incidence of adenocarcinoma in adults and seniors. Can J Public Health. 1997;88:99-104.
19. Rosenberg T, Martel S. Cancer trends from 1972-1991 for Registered Indians living on Manitoba Reserves. Int J Circumpolar Health. 1998; 57[suppl 1]:391-398.
20. Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol 2006; 176:2397-2400.
21. Cooperberg MR, Mallin K, Ritchey J, et al. Decreasing size at diagnosis of stage I renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008;179:2131-2135.
22. Pankhurst T, Howie AJ, Adu D, et al. Incidental neoplasms in renal biopsies. Nephrol Dial Transplant. 2006;21:64-69.
23. Fenton JJ, Weiss NS. Screening computed tomography: will it result in overdiagnosis of renal carcinoma? Cancer. 2004;100:986-990.
24. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiologic evidence. Lung Cancer. 2004;45[suppl 2]: 53-59.
25. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2004.
26. Hunt JD, van der Hel OL, McMillan GP, et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005;114:101-108.
27. Lubin JH, Virtamo J, Weinstein SJ, et al. Cigarette smoking and cancer: intensity patterns in the alpha-tocopherol, beta-carotene cancer prevention study in Finnish men. Am J Epidemiol. 2008; 167:970-975.
28. Parker AS, Cerhan JR, Janney CA, et al. Smoking cessation and renal cell carcinoma. Ann Epidemiol. 2003; 13:245-251.
29. Bjerregaard BK, Raaschou-Nielsen O, Sørensen M, et al. The effect of occasional smoking on smoking-related cancers: in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control. 2006;17:1305-1309.
30. Hu J, Ugnat AM. Active and passive smoking and risk of renal cell carcinoma in Canada. Eur J Cancer. 2005;41:770-778.
31. Sharifi N, Farrar WL. Perturbations in hypoxia detection: a shared link between hereditary and sporadic tumor formation? Med Hypotheses. 2006;66:732-735.
32. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Rev. 2004;4:579-591.
33. Chow WH, Gridley G, Fraumeni JF Jr, et al. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305-1311.
34. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625-1638.
35. Nicodemus KK, Sweeney C, Folsom AR. Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. Int J Cancer. 2004;108:115-121.
36. van Dijk BA, Scheuten LJ, Kiemeney LA, et al. Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands Cohort Study. Am J Epidemiol. 2004; 160:1159-1167.
37. Bjørge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am J Epidemiol. 2004;160:1168-1176.
38. Flaherty KT, Fuchs CS, Colditz GA, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control. 2005;16:1099-1106.
39. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 2005;23:4742-4754.
40. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006;118:728-738.
41. Luo J, Margolis KL, Adami HO, et al. Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women's Health Initiative (United States). Am J Epidemiol. 2007;166:752-759.
42. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134-1144.
43. Setiawan VW, Stram DO, Nomura AMY, et al. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007; 166:932-940.
44. Adams KF, Leitzmann MF, Albanes D, et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol. 2008;168:268-277.
45. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578.
46. Gago-Dominguez M, Castelao JE. Lipid peroxidation and renal cell carcinoma: further supportive evidence and new mechanistic insights. Free Radic Biol Med. 2006;40:721-733.
47. Spyridopoulos TN, Petridou ET, Skalkidou A, et al. Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer. 2007;120:1573-1578.
48. Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008;114:71-83.
49. Steffens J, Bock R, Braedel HU, et al. Renin-producing renal cell carcinomas-clinical and experimental investigations on a special form of renal hypertension. Urol Res. 1992;20:111-115.
50. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and metaanalysis. Lancet Oncol. 2008;9:117-123.
51. Schouten LJ, van Dijk BA, Oosterwijk E, et al. Hypertension, antihypertensives and mutations in the von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study. J Hypertens. 2005;23:1997-2004.
52. Choi MY, Jee SH, Sull JW, et al. The effect of hypertension on the risk for kidney cancer in Korean men. Kidney Int. 2005;67:647-652.
53. Vatten LJ, Trichopoulos D, Holmen J, et al. Blood pressure and renal cancer risk: the HUNT Study in Norway. Br J Cancer. 2007;97:112-114.
54. Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol. 2008;167:438-446.
55. Friis S, Sørensen HT, Mellemkjær L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer. Cancer. 2001;92:2462-2470.
56. Fryzek JP, Poulsen AH, Johnsen SP, et al. A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer. 2005;92:1302-1306.
57. Gago-Dominguez M, Castelao JE, Yuan JM, et al. Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control. 2002;13:287-293.
58. Kaelin WG Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol. 2003;14:2703-2711.
59. Koshiji M, Kageyama Y, Pete EA, et al. HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 2004;23:1949-1956.
60. Mazzali M, Jefferson A, Ni Z, et al. Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension. Kidney Int. 2003;63:2088-2093.
61. Peces R, Martinez-Ara J, Miguel JL, et al. Renal cell carcinoma co-existent with other renal disease: clinico-pathological features in pre-dialysis patients and those receiving dialysis or renal transplantation. Nephrol Dial Transplant. 2004;19:2789-2796.
62. Kojima Y, Takahara S, Miyake O, et al. Renal cell carcinoma in dialysis patients: a single center experience. Int J Urol. 2006;13:1045-1048.
63. Farivar-Mohseni H, Perlmutter AE, Wilson S, et al. Renal cell carcinoma and end stage renal disease. J Urol. 2006;175:2018-2021.
64. Schwarz A, Vatandasiar S, Merkel S, et al. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol. 2007;2:750-756.
65. Neuzillet Y, Lay F, Luccioni A, et al. De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer. 2005;103:251-257.
66. Ianhez LE, Lucon M, Nahas WC, et al. Renal cell carcinoma in renal transplant patients. Urology. 2007;69:462-464.
67. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:476-483.
68. Das A, Thomas S, Zablotska LB, et al. Association of esophageal adenocarcinoma with other subsequent primary cancers. J Clin Gastroenterol. 2006;40:405-411.
69. Thompson RH, Leibovich BC, Cheville JC, et al. Second primary malignancies associated with renal cell carcinoma histological subtypes. J Urol. 2006;176:900-903.
70. Beisland C, Talleraas O, Bakke A, et al. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int. 2006;97:698-702.
71. Bani-Hani AH, Leibovich BC, Lohse CM, et al. Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. J Urol. 2005;173:391-394.
72. Wideroff L, Gridley G, Mellemkjær L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360-1365.
73. Lindblad P, Chow WH, Chan J, et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia. 1999;42:107-112.
74. Zucchetto A, Dal Maso L, Tavani A, et al. History of treated hypertension and diabetes mellitus and risk of renal cell cancer. Ann Oncol. 2007;18:596-600.
75. Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology. 2008;71:118-122.
76. Horiguchi A, Sumitomo M, Asakuma J, et al. 3-Hydroxy-3-methylglutaryl- coenzyme A reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res. 2004;10:8648-8655.
77. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study, Int J Cancer. 2005;114:643-647.
78. Mehta JL, Bursac Z, Hauer-Jensen M, et al. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. Am J Cardiol. 2006;98:923-928.
79. Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1-24.
80. Harris RE, Beebe-Donk J, Doss H, et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade [review]. Oncol Rep. 2005;13:559-583.
81. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control. 2006;17:871-888.
82. Friis S, Nielsen GL, Mellemkjaer L, et al. Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer. 2002;97:96-101.
83. Lambe M, Lindblad P, Wuu J, et al. Pregnancy and risk of renal cell cancer: a population-based study in Sweden. Br J Cancer. 2002;86:1425-1429.
84. Kabat GC, Silvera SA, Miller AB, et al. A cohort study of reproductive and hormonal factors and renal cell cancer risk in women. Br J Cancer. 2007;96:845-849.
85. Molokwu JC, Prizment AE, Folsom AR. Reproductive characteristics and risk of kidney cancer: Iowa Women's Health Study. Maturitas. 2007;58:156-163.
86. Langner C, Ratschek M, Rehak P, et al. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol. 2004;171:611-614.
87. Keller G, Schally AV, Gaiser T, et al. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Clin Cancer Res. 2005;11:5549-5557.
88. Wolf DC, Goldsworthy TL, Dormer EM, et al. Estrogen treatment enhances hereditary renal tumor development in Eker rats. Carcinogenesis. 1998;19:2043-2047.
89. Mahabir S, Leitzmann MF, Pietinen P, et al. Physical activity and renal cell cancer risk in a cohort of male smokers. Int J Cancer. 2004;108:600-605.
90. Moore SC, Chow WH, Schatzkin A, et al. Physical activity during adulthood and adolescence in relation to renal cell cancer. Am J Epidemiol. 2008;168:149-157.
91. Bergström A, Terry P, Lindblad P, et al. Physical activity and risk of renal cell cancer. Int J Cancer. 2001;92:155-157.
92. Bergström A, Moradi T, Lindblad P, et al. Occupational physical activity and renal cell cancer: a nationwide cohort study in Sweden, Int J Cancer. 1999;83:186-191.
93. Jakicic JM, Marcus BH, Gallagher KI, et al. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial. JAMA. 2003;290:1323-1330.
94. Stewart KJ, Bacher AC, Turner KL, et al. Effect of exercise on blood pressure in older persons: a randomized controlled trial. Arch Intern Med. 2005;165:756-762.
95. Mora S, Cook N, Buring JE, et al. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007;116:2110-2118.
96. Fraser GE, Phillips RL, Beeson WL. Hypertension, antihypertensive medications and risk of renal carcinoma in California Seventh-Day Adventists. Int J Epidemiol. 1990;19:832-838.
97. Rashidkhani B, Lindblad P, Wolk A. Fruits, vegetables and risk of renal cell carcinoma: a prospective study of Swedish women. Int J Cancer. 2005;113:451-455.
98. Lee JE, Giovannucci E, Smith-Warner SA, et al. Intakes of fruits, vegetables, vitamins A, C, and E, and carotenoids and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15:2445-2452.
99. van Dijk BA, Scheuten LJ, Kiemeney LA, et al. Vegetable and fruit consumption and risk of renal cell carcinoma: results from the Netherlands cohort study. Int J Cancer. 2005;117:648-654.
100. Weikert S, Boeing H, Pischon T, et al. Fruits and vegetables and renal cell carcinoma: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006;118:3133-3139.
101. van Dijk BA, Schouten LJ, Oosterwijk E, et al. Carotenoid and vitamin intake, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. Cancer Causes Control. 2008;19:125-134.
102. Wolk A, Larsson SC, Johansson JE, et al. Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA. 2006;296:1371-1376.
103. McCabe AJ, Wallace JM, Gilmore WS, et al. Docosahexaenoic acid reduces in vitro invasion of renal cell carcinoma by elevated levels of tissue inhibitor of metalloproteinase-1. J Nutr Biochem. 2005;16:17-22.
104. Skopinska-Rozewska E, Krotkiewski M, Sommer E, et al. Inhibitory effect of shark liver oil on cutaneous angiogenesis induced in Balb/c mice by syngeneic sarcoma L-1, human urinary bladder and human kidney tumour cells. Oncol Rep. 1999;6:1341-1344.
105. Fujioka T, Suzuki Y, Okamoto T, et al. Prevention of renal cell carcinoma by active vitamin D3. World J Surg. 2000;24:1205-1210.
106. Törnqvist M. Acrylamide in food: the discovery and its implications: a historical perspective. Adv Exp Med Biol. 2005;561:1-19.
107. Mucci LA, Dickman PW, Steineck G, et al. Dietary acrylamide and cancer of the large bowel, kidney, and bladder: absence of an association in a population-based study in Sweden. Br J Cancer. 2003;88:84-89.
108. Mucci LA, Dickman PW, Steineck G, et al. Dietary acrylamide and cancer risk: additional data on coffee. Br J Cancer. 2003;89:735-736.
109. Mucci LA, Lindblad P, Steineck G, et al. Dietary acrylamide and risk of renal cell cancer. Int J Cancer. 2004;109:774-776.
110. Hogervorst JG, Schouten LJ, Konings EJ, et al. Dietary acrylamide intake and the risk of renal cell, bladder, and prostate cancer. Am J Clin Nutr. 2008;87:1428-1438.
111. Besaratinia A, Pfeifer GP. A review of mechanisms of acrylamide carcinogenicity. Carcinogenesis. 2007;28:519-528.
112. Wirfalt E, Paulsson B, Törnqvist M, et al. Associations between estimated acrylamide intakes, and hemoglobin AA adducts in a sample from the Malmö Diet and Cancer cohort. Eur J Clin Nutr. 2008;62:314-323.
113. Rashidkhani B, Åkesson A, Lindblad P, et al. Alcohol consumption and risk of renal cell carcinoma: a prospective study of Swedish women. Int J Cancer. 2005;117:848-853.
114. Mahabir S, Leitzmann MF, Virtanen MJ, et al. Prospective study of alcohol drinking and renal cell cancer risk in a cohort of Finnish male smokers. Cancer Epidemiol Biomarkers Prev. 2005;14:170-175.
115. Lee JE, Giovannucci E, Smith-Warner SA, et al. Total fluid intake and use of individual beverages and risk of renal cell cancer in two large cohorts. Cancer Epidemiol Biomarkers Prev. 2006;15:1204-1211.
116. Lee JE, Hunter DJ, Spiegelman D, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst. 2007;99:801-810.
117. Lazarus R, Sparrow D, Weiss ST. Alcohol intake and insulin levels. The Normative Aging Study. Am J Epidemiol. 1997;145:909-916.
118. Davies MJ, Baer DJ, Judd JT, et al. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA. 2002;287:2559-2562.
119. Harm V, Brüning T, Bolt HM. Renal carcinogenicity of trichloroethylene: update, mode of action, and fundamentals for occupational standard setting. Rev Environ Health. 2005;20:103-118.
120. Scott CS, Chiu WA. Trichloroethylene cancer epidemiology: a consideration of select issues. Environ Health Perspect. 2006;114:1471-1478.
121. Charbotel B, Fevotte J, Hours M, et al. Case-control study on renal cell cancer and occupational exposure to trichloroethylene. Part II: epidemiological aspects. Ann Occup Hyg. 2006;50:777-787.
122. Lock EA, Reed CJ. Trichloroethylene: mechanisms of renal toxicity and renal cancer and relevance to risk assessment. Toxicol Sci. 2006;91:313-331.
123. Brauch H, Weirich G, Hornauer MA, et al. Trichloroethylene exposure and sporadic somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst. 1999;91:854-861.
124. Brüning T, Pesch B, Wiesenhütter B, et al. Renal cell cancer risk and occupational exposure to trichloroethylene: results of a consecutive case-control study in Arnsberg, Germany. Am J Ind Med. 2003;43:274-285.
125. Raaschou-Nielsen O, Hansen J, McLaughlin JK, et al. Cancer risk among workers at Danish companies using trichloroethylene: a cohort study. Am J Epidemiol 2003;158:1182-1192.
126. Zhao Y, Krishnadasan A, Kennedy N, et al. Estimated effects of solvents and mineral oils on cancer incidence and mortality in a cohort of aerospace workers. Am J Ind Med. 2005;48:249-258.
127. Boice JD Jr, Marano DE, Cohen SS, et al. Mortality among Rocketdyne workers who tested rocket engines, 1948-1999. J Occup Environ Med. 2006;48:1070-1092.
128. Hansen J, Raaschou-Nielsen O, Christensen JM, et al. Cancer incidence among Danish workers exposed to trichloroethylene. J Occup Environ Med. 2001;43:133-139.
129. Chang YM, Tai CF, Yang SC, et al. A cohort mortality study of workers exposed to chlorinated organic solvents in Taiwan. Ann Epidemiol. 2003;13:652-660.
130. Fevotte J, Charbotel B, Muller-Beaute P, et al. Case-control study on renal cell cancer and occupational exposure to trichloroethylene. Part I: exposure assessment. Ann Occup Hyg. 2006;50:765-775.
131. Chiu WA, Caldwell JC, Keshava N, et al. Key scientific issues in the health risk assessment of trichloroethylene. Environ Health Perspect. 2006;114:1445-1449.
132. Parent ME, Hua Y, Siemiatycki J. Occupational risk factors for renal cell carcinoma in Montreal. Am J Ind Med. 2000;38:609-618.
133. Pesch B, Haerting J, Ranft U, et al. Occupational risk factors for renal cell carcinoma: agent-specific results from a case-control study in Germany. Int J Epidemiol. 2000;29:1014-1024.
134. Buzio L, Tondel M, De Palma G, et al. Occupational risk factors for renal cell cancer. An Italian case-control study. Med Lav. 2002;93:303-309.
135. Hu J, Mao Y, White K. Renal cell carcinoma and occupational exposure to chemicals in Canada. Occup Med. 2002;52:157-164.
136. Mattioli S, Truffelli D, Baldasseroni A, et al. Occupational risk factors for renal cell cancer: a case-control study in northern Italy. J Occup Environ Med. 2002;44:1028-1036.
137. Richard S, Carrette MN, Béroud C, et al. High incidence of renal tumours in vitamins A and E synthesis workers: a new cause of occupational cancer? [Letter]. Int J Cancer. 2004;108:942-944.
138. Zhang Y, Cantor KP, Lynch CF, et al. A population-based case-control study of occupation and renal cell carcinoma risk in Iowa. J Occup Environ Med. 2004;46:235-240.
139. Guo HR, Chiang HS, Hu H, et al. Arsenic in drinking water and incidence of urinary cancers. Epidemiology. 1997;8:545-550.
140. Kurttio P, Pukkala E, Kahelin H, et al. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ Health Perspect. 1999;107:705-710.
141. Baastrup R, Sørensen M, Baistrøom T, et al. Arsenic in drinking-water and risk for cancer in Denmark. Environ Health Perspect. 2008;116:231-237.
142. Ward MH, Rusiecki JA, Lynch CF, et al. Nitrate in public water supplies and the risk of renal cell carcinoma. Cancer Causes Control. 2007;18:1141-1151.
143. Kurttio P, Salonen L, Ilus T, et al. Well water radioactivity and risk of cancers of the urinary organs. Environ Res. 2006;102:333-338.
144. Romanenko A, Morell-Quadreny L, Nepomnyaschy V, et al. Pathology and proliferative activity of renal-cell carcinomas (RCCS) and renal oncocytomas in patients with different radiation exposure after the Chernobyl accident in Ukraine. Int J Cancer. 2000;87:880-883.
145. Romanenko A, Morell-Quadreny L, Nepomnyaschy V, et al. Radiation sclerosing proliferative atypical nephropathy of peritumoral tissue of renal-cell carcinomas after the Chernobyl accident in Ukraine. Virchows Arch. 2001;438:146-153.
146. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317-1320.
147. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68-73.
148. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406-410.
149. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell. 2002;2:157-164.
150. Negri E, Foschi R, Talamini R, et al. Family history of cancer and the risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2441-2444.
151. Hung RJ, Moore L, Boffetta P, et al. Family history and the risk of kidney cancer: a multicenter case-control study in Central Europe. Cancer Epidemiol Biomarkers Prev. 2007;16:1287-1290.
152. Randi G, Pelucchi C, Negri E, et al. Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers. Int J Cancer. 2007;121:2748-2752.
153. Dong C, Hemminki K. Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families. Int J Cancer. 2001;92:144-150.
154. Gudbiartsson T, Jónasdóttir T, Thoroddsen Á, et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer. 2002;100:476-479.
155. Yu W, Gwinn M, Clyne M, et al. A navigator for human genome epidemiology. Nat Genet. 2008;40:124-125.
156. Brüning T, Lammert M, Kempkes M, et al. Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch Toxicol. 1997;71:596-599.
157. Longuemaux S, Deloménie C, Gallou C, et al. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res. 1999;59:2903-2908.
158. Sweeney C, Farrow DC, Schwartz SM, et al. Glutathione S-transferase M1, T1, and P1 polymorphisms as risk factors for renal cell carcinoma: a case-control study. Cancer Epidemiol Biomarkers Prev. 2000;9:449-454.
159. Buzio L, De Palma G, Mozzoni P, et al. Glutathione S-transferases M1-I and T1-I as risk modifiers for renal cell cancer associated with occupational exposure to chemicals. Occup Environ Med. 2003;60: 789-793.
160. Moore LE, Brennan P, Karami S, et al. Glutathione S-transferase polymorphisms, cruciferous vegetable intake and cancer risk in the Central and Eastern European Kidney Cancer Study. Carcinogenesis. 2007;28:1960-1964.
161. Wiesenhütter B, Selinski S, Golka K, et al. Re-assessment of the influence of polymorphisms of phase-II metabolic enzymes on renal cell cancer risk of trichloroethylene-exposed workers. Int Arch Occup Environ Health. 2007;81:247-251.
162. Smits KM, Schouten LJ, van Dijk BA, et al. Polymorphisms in genes related to activation or detoxification of carcinogens might interact with smoking to increase renal cancer risk: results from The Netherlands Cohort Study on diet and cancer. World J Urol. 2008;26:103-110.
163. Karami S, Boffetta P, Rothman N, et al. Renal cell carcinoma, occupational pesticide exposure, and modification by glutathione S-transferase polymorphisms. Carcinogenesis. 2008 [Epub ahead of print].
164. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445-600.
165. Farker K, Lehmann MH, Kästner R, et al. CYP2E1 genotyping in renal cell/urothelial cancer patients in comparison with control populations. Int J Clin Pharmacol Ther. 1998;36:463-468.
166. Semenza JC, Ziogas A, Largent J, et al. Gene-environment interactions in renal cell carcinoma. Am J Epidemiol. 2001;153:851-859.
167. Sasaki M, Tanaka Y, Okino ST, et al. Polymorphisms of the CYP1B1 gene as risk factors for human renal cell cancer. Clin Cancer Res. 2004;10:2015-2019.
168. Ikuyama T, Hamasaki T, Inatomi H, et al. Association of vitamin D receptor gene polymorphism with renal cell carcinoma in Japanese. Endocrine J. 2002;49:433-438.
169. Obara W, Suzuki Y, Kato K, et al. Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population. Int J Urol. 2007;14:483-487.
170. Karami S, Brennan P, Hung RJ, et al. Vitamin D receptor polymorphisms and renal cancer risk in Central and Eastern Europe. J Toxicol Environ Health. 2008;71[part A]:367-372.
171. Trydal T, Bakke A, Aksnes L, et al. 1,25-Dihydroxyvitamin D3 receptor measurement in primary renal cell carcinomas and autologous normal kidney tissue. Cancer Res. 1988;48:2458-2461.
172. Fujioka T, Hasegawa M, Ishikura K, et al. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol. 1998;160:247-251.
173. Hirata H, Hinoda Y, Matsuyama H, et al. Polymorphisms of DNA repair genes are associated with renal cell carcinoma. Biochem Biophys Res Commun. 2006;342:1058-1062.
174. Sakano S, Hinoda Y, Okayama N, et al. The association of DNA repair gene polymorphisms with the development and progression of renal cell carcinoma. Ann Oncol. 2007;18:1817-1827.
175. Rubio-Del-Campo A, Salinas-Sánchez AS, Sánchez- Sánchez F, et al. Implications of mismatch repair genes hMLH1 and hMSH2 in patients with sporadic renal cell carcinoma. BJU Int. 2008;102:504-569.
176. Heijmans BT, Boer JM, Suchiman HE, et al. A common variant of the methylenetetrahydrofolate reductase gene (lp36) is associated with an increased risk of cancer. Cancer Res. 2003;63:1249-1253.
177. Moore LE, Hung R, Karami S, et al. Folate metabolism genes, vegetable intake and renal cancer risk in central Europe. Int J Cancer. 2008;122:1710-1715.
178. Yu J, Habuchi T, Tsuchiya N, et al. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. J Urol. 2004;172:2410-2413.
179. Brennan P, McKay J, Moore L, et al. Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case-control study. Hum Mol Genet. 2007;16:1794-1801.
180. Chen T, Jackson C, Costello B, et al. An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder. Int J Cancer. 2004;112:420-425.
181. Havranek E, Howell WM, Fussell HM, et al. An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma. J Urol. 2005;173:709-712.
182. Bastürk B, Yavasçaoǧlu İ, Vuruskan H, et al. Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine. 2005;30:41-45.
183. Cozar JM, Romero JM, Aptsiauri N, et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol. 2007;68:698-704.
184. Tanaka Y, Hirata H, Chen Z, et al. Polymorphisms of catechol-O- methyltransferase in men with renal cell cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:92-97.
185. Ollerenshaw M, Page T, Hammonds J, et al. Polymorphisms in the hypoxia inducible factor-1α gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet. 2004;153:122-126.
186. Hirata H, Okayama N, Naito K, et al. Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma. Carcinogenesis. 2004;25:2379-2384.
187. Awakura Y, Ito N, Nakamura E, et al. Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett. 2006;241:59-63.
188. Wu X, Amos CI, Zhu Y, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003;95:1211-1218.
189. Shao L, Wood CG, Zhang D, et al. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol. 2007;178:1492-1496.
190. Nickerson ML, Jaeger E, Durocher JA, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14:4726-4734.
191. Charbotel B, Gad S, Caïola D, et al. Trichloroethylene exposure and somatic mutations of the VHL gene in patients with renal cell carcinoma. J Occup Med Toxicol. 2007;2:13-19.
192. van Dijk BA, Schouten LJ, Oosterwijk E, et al. Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. Br J Cancer. 2006;95:374-377.
193. Hemminki K, Jiang Y, Ma X, et al. Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors. Carcinogenesis. 2002;23:809-815.
194. Shiao YH, Rice JM, Anderson LM, et al. von Hippel-Lindau gene mutations in JV-nitroso-dimethylamine-induced rat renal epithelial tumors. J Natl Cancer Inst. 1998;90:1720-1723.
195. Zhu Y, Horikawa Y, Yang H, et al. BPDE induced lymphocytic chromosome 3p deletions may predict renal cell carcinoma risk. J Urol. 2008;179:2416-2421.
196. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85-90.
197. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer. 2005;5:57-67.
198. Banks RE, Tirukonda P, Taylor C, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006;66:2000-2011.
199. Romanenko A, Morell-Quadreny L, Lopez-Guerrero JA, et al. The INK4a/ARF locus: role in cell cycle control for renal cell epithelial tumor growth after the Chernobyl accident. Virchows Arch. 2004;445:298-304.
200. Roth S, Partanen T, Suitiala T, et al. Molecular analysis of occupational cancer: infrequent p53 and ras mutations in renal-cell cancer in workers exposed to gasoline. Int J Cancer. 1997;73:492-496.
201. Peters I, Vaske B, Albrecht K, et al. Adiposity and age are statistically related to enhanced RASSFlA tumor suppressor gene promoter methylation in normal autopsy kidney tissue. Cancer Epidemiol Biomarkers Prev. 2007;16:2526-2532.
202. Mally A, Walker CL, Everitt JI, et al. Analysis of renal cell transformation following exposure to trichloroethene in vivo and its metabolite S-(dichlorovinyl)-L-cysteine in vitro. Toxicology. 2006;224:108-118.
203. Lock EA, Barth J, Argraves SW, et al. Changes in gene expression in human renal proximal tubule cells exposed to low concentrations of S-(1,2-dichlorovinyl)-L-cysteine, a metabolite of trichloroethylene. Toxicol Appl Pharmacol. 2006;216:319-330.
204. Yoshimoto T, Matsuura K, Kaman S, et al. High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. J Pathol. 2007;213:392-401.
205. Cifola I, Spinelli R, Beltrame L, et al. Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer. 2008;7:6-17.
206. Monzon FA, Hagenkord JM, Lyons-Weiler MA, et al. Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors. Mod Pathol. 2008;21:599-608.